Skip to content

Dynamic changes of serum Galectin-3 and miR-126 in acute ischemic stroke patients treated with or without edaravone dexborneol

Dynamic changes of serum galectin-3 and miR-126 and their clinical associations in acute ischemic stroke patients treated with or without edaravone dexborneol: a prospective pilot study - GM-AIS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125887
Enrollment
Unknown
Registered
2026-06-01
Start date
2023-09-26
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Treatment group:Patients received edaravone dexborneol in addition to standard stroke management
the actual dosing regimen and treatment duration were recorded according to routine clinical practice.
Control group:Patients received standard stroke management alone.

Sponsors

Chengdu Sixth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Diagnosis of acute ischemic stroke confirmed by cranial CT or MRI; 3. Onset-to-enrollment time <=48 hours; 4. Pre-stroke mRS <=1; 5. No mechanical thrombectomy or intra-arterial thrombolysis before enrollment; 6. Written informed consent provided by the patient or legal representative; 7. Agreement to clinical data collection, blood sampling, and 90-day follow-up; 8. Receipt of standard stroke management during the study period, with or without edaravone dexborneol according to random allocation.

Exclusion criteria

Exclusion criteria: 1. Imaging-confirmed acute intracranial hemorrhagic disease; 2. Intra-arterial thrombolysis or mechanical thrombectomy; 3. Pregnancy, lactation, or planned pregnancy within 90 days; 4. Severe renal dysfunction (e.g., eGFR <30 ml/min); 5. Malignant tumor or severe systemic disease with expected survival <90 days; 6. Active severe infection; 7. Severe psychiatric disorder or dementia preventing informed consent or follow-up; 8. Known allergy or contraindication to edaravone dexborneol or its components; 9. Any other condition judged by the investigators to make the participant unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale (mRS) at 90 days;

Secondary

MeasureTime frame
National Institutes of Health Stroke Scale (NIHSS) score at admission;National Institutes of Health Stroke Scale (NIHSS) score Day7 of admission ;serum miR-126 level at admission;serum miR-126 level Day7 of admission;serum galectin-3 level at admission;serum galectin-3 level Day7 of admission;Barthel Index score at admission;Barthel Index score Day7 of admission;

Countries

China

Contacts

Public ContactHe Yuting

Chengdu Sixth People's Hospital

heyuting1219@163.com+86 185 0283 0559

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026